127 related articles for article (PubMed ID: 37403986)
1. Systemic delivery of specific and efficient CRISPR/Cas9 system targeting HPV16 oncogenes using LL-37 antimicrobial peptide in C57BL/6 mice.
Khairkhah N; Bolhassani A; Rajaei F; Najafipour R
J Med Virol; 2023 Jul; 95(7):e28934. PubMed ID: 37403986
[TBL] [Abstract][Full Text] [Related]
2. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer.
Ling K; Yang L; Yang N; Chen M; Wang Y; Liang S; Li Y; Jiang L; Yan P; Liang Z
Hum Gene Ther; 2020 Mar; 31(5-6):297-308. PubMed ID: 31989837
[TBL] [Abstract][Full Text] [Related]
3. Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells.
Cheng YX; Chen GT; Yang X; Wang YQ; Hong L
Curr Med Sci; 2018 Apr; 38(2):212-221. PubMed ID: 30074178
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice.
Jubair L; Lam AK; Fallaha S; McMillan NAJ
PLoS One; 2021; 16(1):e0223288. PubMed ID: 33411765
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
[TBL] [Abstract][Full Text] [Related]
6. Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes.
Zhen S; Liu Y; Lu J; Tuo X; Yang X; Chen H; Chen W; Li X
Hum Gene Ther; 2020 Mar; 31(5-6):309-324. PubMed ID: 31973584
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9.
Zhen S; Hua L; Takahashi Y; Narita S; Liu YH; Li Y
Biochem Biophys Res Commun; 2014 Aug; 450(4):1422-6. PubMed ID: 25044113
[TBL] [Abstract][Full Text] [Related]
8. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
9. In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line.
Zhen S; Lu JJ; Wang LJ; Sun XM; Zhang JQ; Li X; Luo WJ; Zhao L
Transl Oncol; 2016 Dec; 9(6):498-504. PubMed ID: 27816686
[TBL] [Abstract][Full Text] [Related]
10. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells.
Hu Z; Yu L; Zhu D; Ding W; Wang X; Zhang C; Wang L; Jiang X; Shen H; He D; Li K; Xi L; Ma D; Wang H
Biomed Res Int; 2014; 2014():612823. PubMed ID: 25136604
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-based inactivation of human papillomavirus oncogenes E6 or E7 induces senescence in cervical cancer cells.
Inturi R; Jemth P
Virology; 2021 Oct; 562():92-102. PubMed ID: 34280810
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.
Kennedy EM; Kornepati AV; Goldstein M; Bogerd HP; Poling BC; Whisnant AW; Kastan MB; Cullen BR
J Virol; 2014 Oct; 88(20):11965-72. PubMed ID: 25100830
[TBL] [Abstract][Full Text] [Related]
13. Systemic Delivery of CRISPR/Cas9 Targeting HPV Oncogenes Is Effective at Eliminating Established Tumors.
Jubair L; Fallaha S; McMillan NAJ
Mol Ther; 2019 Dec; 27(12):2091-2099. PubMed ID: 31537455
[TBL] [Abstract][Full Text] [Related]
14. Blocking activity of the HPV18 virus in cervical cancer cells using the CRISPR/Cas9 system.
Wang J; Guo M; Wang Q; Dang J; Liu X; Jin Z
Int J Clin Exp Pathol; 2018; 11(8):4230-4235. PubMed ID: 31949818
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer.
Zhen S; Li X
Cell Physiol Biochem; 2017; 44(6):2455-2466. PubMed ID: 29268281
[TBL] [Abstract][Full Text] [Related]
16. The application of CRISPR/Cas9 system in cervical carcinogenesis.
Gao C; Wu P; Yu L; Liu L; Liu H; Tan X; Wang L; Huang X; Wang H
Cancer Gene Ther; 2022 May; 29(5):466-474. PubMed ID: 34349239
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of mouse and human preimplantation development following POU5F1 CRISPR/Cas9 targeting reveals interspecies differences.
Stamatiadis P; Boel A; Cosemans G; Popovic M; Bekaert B; Guggilla R; Tang M; De Sutter P; Van Nieuwerburgh F; Menten B; Stoop D; Chuva de Sousa Lopes SM; Coucke P; Heindryckx B
Hum Reprod; 2021 Apr; 36(5):1242-1252. PubMed ID: 33609360
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral Vectors Armed with PAPILLOMAVIRUs Oncogene Specific CRISPR/Cas9 Kill Human-Papillomavirus-Induced Cervical Cancer Cells.
Ehrke-Schulz E; Heinemann S; Schulte L; Schiwon M; Ehrhardt A
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708897
[TBL] [Abstract][Full Text] [Related]
19. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Wang SW; Gao C; Zheng YM; Yi L; Lu JC; Huang XY; Cai JB; Zhang PF; Cui YH; Ke AW
Mol Cancer; 2022 Feb; 21(1):57. PubMed ID: 35189910
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6.
Yoshiba T; Saga Y; Urabe M; Uchibori R; Matsubara S; Fujiwara H; Mizukami H
Oncol Lett; 2019 Feb; 17(2):2197-2206. PubMed ID: 30675284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
